Results 31 to 40 of about 4,011 (178)

Synthetic routes to treprostinil N-acyl methylsulfonamide [PDF]

, 2020
The synthesis of the prodrug candidate, treprostinil N-acyl methylsulfonamide 5 was accomplished from treprostinil 2 utilising protecting group strategies.
Shen, L, Clapp, LH, Picken, C, Brocchini, S, Laing, P   +4 more
core   +1 more source

Treprostinil alleviates hepatic mitochondrial injury during rat renal ischemia-reperfusion injury [PDF]

, 2021
Background: Renal ischemia-reperfusion injury (IRI) causes acute kidney injury as well as liver injury. Renal IRI depletes hepatic antioxidants, promotes hepatic inflammation and dysfunction through Tlr9 upregulation.
Tolbert,, Ghonem, Nisanne S., Evelyn Tolbert, Nisanne S. Ghonem, Hou, Joyce, Tolbert, Evelyn, Birkenbach, Mark, Mark Birkenbach, Joyce Hou   +8 more
core   +1 more source

Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil

Pulmonary Circulation, 2020
A dry-powder inhaled formulation of treprostinil (LIQ861) produced using PRINT® technology offers a substantial advantage over current nebulized therapy.
Robert Roscigno, Toby Vaughn, Stephanie Anderson, William Wargin, Thomas Hunt, Nicholas S. Hill   +5 more
doaj   +1 more source

Abnormal platelet aggregation in pediatric pulmonary hypertension

Pulmonary Circulation, 2022
Endogenous prostacyclin stimulates pulmonary vasodilation and inhibits platelet aggregation. For the synthetic analog treprostinil, used in the treatment of pulmonary hypertension (PH), conflicting, anecdotal evidence exists regarding its effects on ...
Stephanie S. Handler, Jing Jin, Michelle T. Ogawa, Jeffrey A. Feinstein, Clara Lo   +4 more
doaj   +1 more source

Prodrug approaches to reduce treprostinil toxicity [PDF]

, 2019
Pulmonary arterial hypertension is a chronic inflammatory condition of the peripheral pulmonary vessels which is thought to affect up to 52 in every million people. Vasoconstriction, proliferation and vascular remodelling mechanisms dominate which narrow
Picken, Christina
core   +1 more source

Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension

, 2023
Pulmonary arterial hypertension (PAH), a rare vasculopathy progressively leading to right heart failure and death, is associated with considerable economic burden.
Yuen Tsang (8081498), Xing Liu (221084), Eros Papademetriou (11582634), Ravi Potluri (6913097), Amélie Beaudet (9180385), Sumeet Panjabi (8676261)   +5 more
core   +1 more source

A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension

Therapeutic Advances in Respiratory Disease, 2021
Background and aims: Treprostinil is a prostacyclin analog used to treat pulmonary arterial hypertension. Dosing is empiric and based on tolerability. Adverse effects are common and can affect treatment persistence.
James C. Coons, Karryn Crisamore, Solomon Adams, Ashley Modany, Marc A. Simon, Wenchen Zhao, Imam H. Shaik, Raman Venkataramanan, Philip E. Empey   +8 more
doaj   +1 more source

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil [PDF]

ERJ Open Research, 2020
Cough is induced by inhaled prostacyclin analogues including treprostinil (TRE), and, at higher doses, treprostinil palmitil (TP), a prodrug of TRE. In this report, we have investigated mechanisms involved in TRE- and TP-induced cough, using a dry powder formulation of TP (TPIP) to supplement previous data obtained with an aqueous suspension ...
Richard W. Chapman, Michel R. Corboz, Carlos Fernandez, Eugene Sullivan, Andy Stautberg, Adam J. Plaunt, Donna M. Konicek, Vladimir Malinin, Zhili Li, David Cipolla, Walter Perkins   +10 more
openaire   +3 more sources

Treprostinil inhibits functional activation of scleroderma (SSc) vascular smooth muscle cells (vSMCs) by inhibiting Yap and activating PPARG signaling.

Translation, 2023
Background: Progressive vascular wall thickness and fibrosis are the hallmarks of SSc vasculopathy. Overexpression of TGFB1 in SSc and activation of vSMCs are important steps in the pathogenesis of SSc vascular disease.
yongqing wang, Bashar Kahaleh
doaj   +1 more source

Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension. [PDF]

, 2023
INTRODUCTION: In the event-driven FREEDOM-EV trial, oral treprostinil delayed clinical worsening in patients with pulmonary arterial hypertension (PAH).
Grover, Rob, Grünig, Ekkehard, Balasubramanian, Vijay, Shen, Jieyan, Yuanhua, Yang, Pepke-Zaba, Joanna, Vonk, Madelon, Yu, Zaixin, White, R James, for the FREEDOM-EV Investigators, Ousmanou, Aliou, Deng, Chunqin, Broderick, Meredith, Yao, Hua, Cadaret, Linda, Vizza, Carmine Dario, Rosenkranz, Stephan, Seaman, Scott, Rahaghi, Franck, Hage, Antoine, Elwing, Jean, Lordan, James   +21 more
core   +5 more sources